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Objectives. Protein-energy malnutrition as a consequence of deﬁcient protein intake frequently occurs in peritoneal dialysis (PD)
patients.Previously,weshowedthatperitonealdialysatecontainingamixtureofaminoacids(AA)andglucosehasanaboliceﬀects.
However AA-dialysate has been reported to increase intraperitoneal protein and AA losses and the release of proinﬂammatory
cytokines (interleukine-6 (IL-6) and tumor necrosis factor alpha (TNFα)). We investigated the eﬀect of AA plus glucose (AAG)
solutions on peritoneal protein losses and cytokine generation. Methods. In 6 patients on standard automated peritoneal dialysis
(APD) 12 APD sessions of 6 cycles each were performed during the night using dialysate containing 1.1% AA plus glucose or
glucose alone as control. Protein losses and TNFα and IL-6 concentrations were measured in dialysates separately collected from
nightly cycling and daytime dwell. Results. The 24hour-protein losses with AAG (median 6.7g, range 4.7–9.4g) were similar to
control dialysate (median 6.0g, range 4.2–9.2g). Daytime dialysate IL-6 levels were higher after nightly AAG dialysis than after
control dialysis (142pg/ml and 82pg/ml, respectively, P<. 05). TNFα concentrations were very low. Conclusion. Nightly APD
with amino acids containing dialysate was associated with an increase in peritoneal IL-6 generation during the day. The addition
of AA to standard glucose dialysis solutions did not induce a signiﬁcant increase of peritoneal protein losses.
Copyright © 2007 H. L. Tjiong et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
One of theuntoward eﬀectsof peritonealdialysis (PD) is th-
eloss of proteins and amino acids into the dialysate eﬄu-
ent. Patients undergoing continuous ambulatory peritoneal
dialysis (CAPD) lose amino acids, 2–4g a day, and a sub-
stantial amount of proteins, varying between 5–15gram per
day. The protein and AA losses increase during peritoni-
tis [1–9]. The continuous loss of proteins and amino acid
through peritoneal clearance can be compensated by ade-
quate dietary intake, but a poor appetite limits protein intake
in many patients [10]. Previously we showed that the gain in
protein provided by supplying amino acids (AA) plus glu-
cose (G) intraperitoneally exceeds the usual 24hours protein
and AA losses through peritoneal clearance [11]. However, it
has been reported that AA-based dialysate may increase in-
traperitoneal protein losses, as well as stimulating the release
ofvariousvasoactivesubstancesincludingseveralproinﬂam-
matory cytokines [12–15].
In this study we investigated the protein losses into
overnight and daytime dialysate eﬄuents and changes in the
levels of the cytokines TNFα a n dI L - 6i ne ﬄuent and in
plasma, comparing dialysate containing AA plus G (AAG)
with glucose (G) only solutions in patients on APD. Ad-
ditionally we determined the peritoneal AA losses into the
overnight and daytime eﬄuents using standard glucose-
based dialysis solution.
2. PATIENTS AND METHODS
2.1. Patients
Six patients who had been on APD for more than 3 months
and had a weekly Kt/V greater than 1.7 were recruited from
the Peritoneal Dialysis Unit of the Erasmus Medical Center
(Rotterdam, the Netherlands). Patients who had had peri-
tonitis or other infectious or inﬂammatory diseases in the
previous 6 weeks, a malignancy, or a life expectancy <6m o n -
ths were excluded. The Medical Ethical Committee of2 Mediators of Inﬂammation
Erasmus MC approved the study and written informed con-
sent was obtained from all patients.
2.2. Studydesign
This study was a part of our previous open label, random-
ized, crossover single center study of the eﬀects of dialysate
containing AA plus G (Nutrineal 1.1% plus Physioneal 1.36–
3.86% G (Baxter BV, Utrecht, the Netherlands) on whole
body protein metabolism, compared with a control solution
containing G alone (Physioneal 1.36%–3.86%). Prior to the
study all patients were treated with standard glucose-based
dialysis ﬂuid (Dianeal or Physioneal, Baxter BV, Utrecht, the
Netherlands). After the patients were randomized to start
with either AAG or with G (concentration of 1.36%–3.86%
depending on the ultraﬁltration targets) each ﬂuid was used
in two consecutive periods of 7 days. The APD schedule for
each patient before and during the study was kept constant.
The dialysis procedure during the study was as follows.
Six nighttime exchanges were performed automaticallyusing
a cycler (HomeChoice, Baxter BV). In the daytime, all pa-
tients, except for one patient, were treated with polyglucose-
containing dialysate (Extraneal, Baxter BV). Two patients
had an additional exchange with glucose solution (Phy-
sioneal). The APD schedule for each patient was simi-
lar to that used before the study in order to meet ade-
quacy and ultraﬁltration targets. The cycler regulated the
mixing procedure. The AA 1.1% solution contained as
buﬀer 40mmol/L lactate and the 1.36%, 2.27%, or 3.86%
G-solutions 25mmol/L bicarbonate, plus 15mmol/L lactate.
At the end of each study week after an overnight fast us-
ing either AAG or G only dialysate and before the morn-
ing exchange, venous blood samples were taken for deter-
mination of the levels of C-reactive protein and the cy-
tokines, interleukine-6 (IL-6), and tumor necrosis factor
alpha (TNFα). In all 6 patients overnight and daytime
dialysates were collected separately during the last three days




Concentrations of C-reactive protein and dialysate protein
were determined by particle-enhanced immunoturbidimet-
ric assay. The dialysate amino acids were analysed by ion ex-
change chromatography on a Biochrome 20 aminoacid anal-
yser (Biochrom, Cambridge, UK) with UV-V is detection us-
ing ninhydrin.
2.3.2. Cytokines
For measurement of TNFα and IL-6, plasma and dialysis
ﬂuidsampleswerediluted1:1inappropriatecalibratordilu-
ent assay buﬀer. Cytokine assays were performed following
the manufacturers protocol (Pelikine human ELISA compact
kits for IL-6 (cat. no. M1906) and TNFα (cat. no. M1920),
Sanquin, Amsterdam, the Netherlands). The standard curve




tional toolkits (Pelikine-Tool set (cat. no. M1980)). Follow-
ing the manufacturers assay instruction step by step, at the
end of the procedure the absorbance per well was measured
at 450nm with a Medgenix ELISA reader. Sample concentra-
tions were calculated using the appropriate standard calibra-
tion lines and the Softmax software of the reader.
3. STATISTICAL ANALYSIS
Data were analyzed using the statistical program SPSS, ver-
sion 14.0, for Windows (SPSS Inc., Chicago, Ill, USA). Data
are expressed as median with range. Comparisons of out-
comes were made using the Wilcoxon Signed Rank test. All
tests of signiﬁcance were two-sided, and diﬀerences were
consideredstatisticallysigniﬁcantwhenthe P valuewas<.05.
4. RESULTS
Table 1 shows the baseline characteristics of the patients,
including the peritoneal membrane characteristics as mea-
sured by peritoneal equilibrium test (PET) [11]. Three pa-
tients were anuric. Apart from the use of medication regu-
larly taken by PD patients, two patients used prednisone in
a maintenance dose. Peritoneal ultraﬁltration after adminis-
tration of AAG-based dialysis ﬂuid, determined as the dif-
ference between dialysate inﬂow and outﬂow, did not diﬀer
from that with G only dialysate. Serum C-reactive protein
levels ranged from 6–65mg/L (median 7.5mg/L) with AAG-
based dialysate and from 1 to 33mg/L (median 9.5mg/L) us-
ing G only dialysate. The protein losses per 24hours, that is,
daytime dwell plus overnight APD with standard G solution
ranged from 4.2 to 9.2g (median 6.0g) were not signiﬁcantly
diﬀerent from that occurring with AAG, which ranged from
4.7 to 9.4g (median 6.7g). As shown in Table 2, there was no
diﬀerence in protein losses between the dialysates. The ap-
pearance rate of protein losses in the overnight eﬄuent was
signiﬁcantly higher than that in the daytime. The mean total
AA losses, that is, essential AA (EAA) and nonessential AA
(NEAA) per 24hours, that is, daytime dwell plus overnight
APD with standard G solution varied between 1.7 and 3.2g
(median 2.2g), and 26 ± 1.7% of dialysate AA were essen-
tial AA. Using standard G only dialysis solution, the total AA
losses in the 8.5hour-overnight eﬄuents were higher than
in the 15.5hour-daytime eﬄuents. Likewise, the appearance
rate of total AA losses into overnight dwells was signiﬁcantly
higherthanthatintodaytimedwells(Table 2).ThetotalEAA
losses in the overnight dwell were also higher than that in
daytime dwell. In particular, IL-6 levels in daytime eﬄu-
ents were signiﬁcantly higher than those in plasma (Table 3).
Dialysate IL-6 concentrations at daytime dwell diﬀered sig-
niﬁcantly from overnight dwell during both type of dialysis
schemes.TheIL-6levelsinthedaytimeeﬄuents afternightly
cycling with AAG were signiﬁcantly higher than that after
G. Plasma and both overnight and daytime eﬄuent levels ofH. L. Tjiong et al. 3
Table 1: Baseline characteristics of the patientsa.
Patient Primary diagnose of renal disease Time on PD (months) Gender Age (years) BMI (wt/ht2) Kt/V (weekly) PET
1 Nephrosclerosis 14 M 57 23.9 1.95 HA
2 Reﬂux nephropathy 8 M 43 25.1 1.85 HA
3 Alport disease 63 M 35 25.9 1.82 H
4 Rapidly progressive glomerulonephitis 45 M 56 22.8 2.04 H
5 Periarteritis nodosa 5 M 47 22.1 1.76 HA
6 Polycystic disease 36 F 45 30.1 1.98 HA
Mean 29 47 25 2
SD 23 8 3 0.1
aM ,m a l e ;F ,f e m a l e ;B M I( w t / h t 2), body mass index (weight/height2); PD, peritoneal dialysis; Kt/V is the urea clearance adjusted for distribution volume,
using PD adequest 2.0, software Baxter11; PET, peritoneal equilibrium test; H, high; HA, high average.
Table 2: Protein and amino acid losses in dialysis eﬄuent in APD patientsa.
Overnight Daytime
AAG dialysis (1) G dialysis (2) After AAG dialysis (3) After G dialysis (4)
Protein (g/8.5h) 3.06 (2.28–3.51) 3.0 (1.84–3.99) 3.48 (2.44–6.16) 3.03 (2.17–5.54)
Protein (g/h) 0.36 (0.27–0.41) 0.35 (0.22–0.47)b 0.22 (0.16–0.40) 0.20 (0.14–0.36)
Total AA (g/8.5h) 1.47 (1.02–1.94)c 0.70 (0.62–1.25)
EAA (g/8.5h) 0.37 (0.25–0.55)d 0.18 (0.17–0.37)
Total AA (g/h) 0.17 (0.12–0.23)e 0.05 (0.04–0.08)
aData are expressed as median and range; AAG, amino acid and glucose; G, glucose.
Comparisons were made for columns (2) versus (4). These resulted in signiﬁcant diﬀerences for b, c, d, and e (P <.05 versus daytime after G).
No signiﬁcant diﬀerences were found for columns (1) versus (2) and (3) versus (4).
tumor necrosis factor α (TNFα) were low using both AAG
and G-only dialysis solutions.
5. DISCUSSION
As part of previous work on the eﬀects of amino acids con-
taining dialysate on whole body protein metabolism, we in-
vestigated in this study the loss of proteins in dialysate in
APD patients using either the standard dialysate containing
only glucose or a mixture of amino acids and glucose. In ad-
dition, we studied the eﬀects of these dialysis ﬂuids on the
peritoneal release of the cytokines IL-6 and TNFα and we in-
vestigated the losses of amino acids with the use of glucose-
based (standard) dialysis solution. Although APD is widely
used,the peritonealprotein losseshavebeenstudiedonly oc-
casionally in adult patients undergoing APD.
We found that the mean protein losses per 24hours, that
is, the sum of daytime dwell and nightly APD with stan-
dard glucose dialysate was on average about 6grams, which
is in the same order of magnitude as previously reported for
CAPD patients by various authors [3, 4]. The peritoneal pro-
tein losses during 8.5hour nightly APD and in the daytime
dwell of 15.5hour were similar. By comparison, in a recent
study, protein losses during nightly cycling were found to
be rather high, exceeding protein losses during the daytime
dwell [16]. Yet, also in our patients protein losses per time
were higher during cycling with standard glucose solution.
This mayseemsurprising asitis generallyacceptedthatperi-
toneal protein losses, in contrast to small molecular weight
solutes, are linear with time irrespective of the number of
dialysate exchanges. It has, however, been shown in patients
on intermittent peritoneal dialysis (IPD) that protein loss is
greater during the ﬁrst dwell after a “dry” period and stabi-
lizes at lower levels after a few exchanges. This ﬁnding could
be explained by wash out of proteins from the previous dry
period [17, 18]. Assuming a residual volume of 400–500mL
in our patients, wash out of proteins from the long daytime
dwell could account for the diﬀerence of protein losses per
time between day time dwell and nighttime cycling.
In previous studies we showed that the amino acids plus
glucose containing dialysis ﬂuid has anabolic eﬀects on pro-
tein metabolism [11, 19]. The current study shows that the
presence of amino acids in the dialysate did not increase pro-
tein loss in the overnight dialysate eﬄuent as compared with
G only dialysis solutions in APD patients. Others have re-
ported that a 2.6% amino acid peritoneal dialysis solution
induced an increased loss of macromolecules including al-
bumin and IgG and the small molecular weight amino acids,
which was accompanied by an increased prostanoid genera-
tion in the peritoneal cavity [12]. One percent AA solutions
were also found to stimulate protein losses and release of
prostanoids and several proinﬂammatory cytokines consis-
tent with an increase in peritoneal blood ﬂow and eﬀective
peritoneal surfacearea [13, 14]. In some studies, however, no
signiﬁcant eﬀect on protein losses or release of prostanoids
was found [20, 21].4 Mediators of Inﬂammation
Table 3: IL-6 and TNFα levels in plasma and dialysatea.
Overnight Daytime
Plasma AAG (1) Plasma G (2) Dialysate AAG (3) Dialysate G (4) After dialysate AAG (5) After dialysate G (6)
IL-6 (pg/mL) 13 (4–26) 13 (3–48) 21 (16–59) 17 (13–40) 142 (71–599)b,d,f 82 (51–338)c,e
IL-6 (ng) 247 (206–784) 197 (168–536) 343 (240–1613) 178 (133–872)
TNFα (pg/mL) 2 (1–52) 2 (1–49) 1 (1–1) 1 (0–2) 2 (1–39) 2 (1– 5)
TNFα (ng) 15 (9–18) 14 (5–21) 5 (2–93) 5 (2–12)
aData are expressed as median and range. AAG, amino acid and glucose; G, glucose; IL-6, interleukine-6; TNFα, tumor necrosis factor α.
Comparisons for IL-6 (pg/mL) were made for columns (1) versus (5), (2) versus (6), (3) versus (4), (5) versus (6), (3) versus (5), (4) versus (6), and (5) versus
(6).
These resulted in signiﬁcant diﬀerences for b (P < . 0 5v e r s u sp l a s m aA A G ) ;c( P < . 0 5v e r s u sp l a s m aG ) ;d( P < .05 versus overnight dialysate AAG); e (P < .05
versus overnight dialysate G); f (P <.05 versus daytime after dialysate G).
No signiﬁcant diﬀerences were found for columns (1) versus (3) and (2) versus (4).
Reports on the peritoneal losses of AA in APD are scarce.
Inourpresentstudythemean24-hourAAlosses,thatis,day-
time dwell and nightly APD were similar as reported earlier
in patients who are on CAPD and somewhat higher com-
pared with a previous report in APD patients, using stan-
dard G dialysis solution [1, 2, 16]. We found that total AA
losses were greater during nightly APD than during the long
daytime dwell with standard G-based dialysis solution. This
ﬁnding is in line with the fact that transperitoneal trans-
port of small molecular weight solutes is dependent on the
dialysate ﬂow rate, that is, number of dialysate exchanges.
Approximately 26% of the eﬄuent AA were essential AA in
agreement with previous ﬁndings in patients on CAPD [1].
We also studied the inﬂuence of amino acid-based
dialysate on cytokines both during the night- and at day-
time. The levels of TNFα and IL-6 as found in the present
study in daytime dialysate are on the whole comparable to
those described in several studies in CAPD patients with
standard glucose dialysis solutions during an infection-free
period [13, 22–24]. Daytime dialysate IL-6 levels were sig-
niﬁcantly higher when during the preceding nightly APD
dialysatewasusedthatcontainedaminoacidsinsteadofonly
glucose. This ﬁnding may be somewhat puzzling as during
nightly cycling no statistically signiﬁcant diﬀerence in IL-6
levels was found. It cannot be ruled out, however, that any
eﬀect of AA on IL-6 during cycling was diluted by rather
low IL-6 concentrations as a result of the high dialysate ﬂow
rate. It has been shown in several studies in CAPD that
amino acid dialysate was accompanied with increased lev-
els of various cytokines including IL-6 and TNFα [13, 25].
There is ample evidence that even in the absence of peri-
tonitis IL-6 is produced locally within the peritoneal cav-
ity rather than transported across the peritoneal membrane.
Our ﬁnding that IL-6 levels in dialysate were higher than in
plasma, especially during the long daytime dwell, are con-
sistent with local production and release [22, 23]. The main
source of peritoneal TNFα is thought to be the mononuclear
phagocyte, whereas both mesothelial cells and macrophages
are able to produce and release substantial amounts of IL-
6[ 23, 26]. The release of IL-6 from mesothelial cells oc-
curs constitutively and can be stimulated by macrophage-
derived TNFα and IL-1β [13, 23, 26]. In the dialysate of pa-
tients with PD-related peritonitis and in ascites of liver cir-
rhosis patients with spontaneous bacterial peritonitis, high
levels of various cytokines including TNFα and IL-6 are
found due to increased local production [23, 26–28]. In
the present study, the patients were clinically free of infec-
tion, and C-reactive protein levels in most of the patients
were normal or only slightly increased. Dialysate TNFα was
very low both with the standard glucose and the amino
acid and glucose mixture. The clinical implications of in-
creased intraperitoneal IL-6 levels are far from straightfor-
ward. Any increases in levels of cytokines in dialysate in vivo
may be interpreted as a sign of a local inﬂammatory stim-
ulus or as an improvement of the capacity to synthesize in-
ﬂammatory factors. It is therefore a matter of debate as to
whether any changes in cytokine release should be consid-
ered as harmful or as a marker of improved tissue respon-
siveness.
In conclusion, our study suggests that in APD the use of
dialysis ﬂuid containing a mixture of amino acids and glu-
cose induces an increase in peritoneal production of IL-6 as
compared to dialysate containing only glucose. In contrast,
no appreciable amounts of TNFα were found in peritoneal
dialysate. This is the ﬁrst controlled study to investigate the
eﬀects of amino acids containing dialysate on cytokines and
protein losses. A limitation of this study is the small number
of patients. Further studies are required to elucidate the re-
lationship between amino acids containing dialysate and the
cytokine network of the peritoneal cavity.
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